Paper40964320
General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants.
Tedman A and 12 others. bioRxiv, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants. Papers, record 40964320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40964320
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| F31 HL162483 | NHLBI NIH HHS | United States | F31HL162483 | PubMed and NIH | NIH RePORTER |
| R01 HL167046 | NHLBI NIH HHS | United States | R01HL167046 | PubMed and NIH | NIH RePORTER |
| R35 GM133552 | NIGMS NIH HHS | United States | R35GM133552 | PubMed | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Updated in | 41379933 | General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants. | https://conductscience.org/library/papers/41379933 |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37730207 | CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine. | ACS Chem Biol | 2023 | https://conductscience.org/library/papers/37730207 | PubMed |
| 2 | 33781744 | The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue. | J Biol Chem | 2021 | https://conductscience.org/library/papers/33781744 | PubMed |
| 3 | 11423120 | Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. | FEBS Lett | 2001 | https://conductscience.org/library/papers/11423120 | PubMed |
| 4 | 18716059 | Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2. | Mol Biol Cell | 2008 | https://conductscience.org/library/papers/18716059 | PubMed |
| 5 | 35327663 | Structural Comparative Modeling of Multi-Domain F508del CFTR. | Biomolecules | 2022 | https://conductscience.org/library/papers/35327663 | PubMed |
| 6 | 28335006 | A platform for functional assessment of large variant libraries in mammalian cells. | Nucleic Acids Res | 2017 | https://conductscience.org/library/papers/28335006 | PubMed |
| 7 | 29099344 | Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. | N Engl J Med | 2017 | https://conductscience.org/library/papers/29099344 | PubMed |
| 8 | 15923638 | Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. | Mol Cell Biol | 2005 | https://conductscience.org/library/papers/15923638 | PubMed |
| 9 | 27168400 | Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect. | PLoS Biol | 2016 | https://conductscience.org/library/papers/27168400 | PubMed |
| 10 | 27660821 | Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases. | JCI Insight | 2016 | https://conductscience.org/library/papers/27660821 | PubMed |
| 11 | 38388235 | In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis. | J Cyst Fibros | 2024 | https://conductscience.org/library/papers/38388235 | PubMed |
| 12 | 40261935 | Proteostasis landscapes of cystic fibrosis variants reveal drug response vulnerability. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40261935 | PubMed |
| 13 | 19307599 | N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. | J Cell Biol | 2009 | https://conductscience.org/library/papers/19307599 | PubMed |
| 14 | 33468668 | Positive epistasis between disease-causing missense mutations and silent polymorphism with effect on mRNA translation velocity. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/33468668 | PubMed |
| 15 | 39388263 | Ribosomal frameshifting selectively modulates the assembly, function, and pharmacological rescue of a misfolded CFTR variant. | Proc Natl Acad Sci U S A | 2024 | https://conductscience.org/library/papers/39388263 | PubMed |
| 16 | 37253358 | General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants. | Cell Chem Biol | 2023 | https://conductscience.org/library/papers/37253358 | PubMed |
| 17 | 32285592 | Calnexin cycle - structural features of the ER chaperone system. | FEBS J | 2020 | https://conductscience.org/library/papers/32285592 | PubMed |
| 18 | 37690692 | Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics. | J Biol Chem | 2023 | https://conductscience.org/library/papers/37690692 | PubMed |
| 19 | 26676362 | N-Glycan-based ER Molecular Chaperone and Protein Quality Control System: The Calnexin Binding Cycle. | Traffic | 2016 | https://conductscience.org/library/papers/26676362 | PubMed |
| 20 | 35389766 | Distinct proteostasis states drive pharmacologic chaperone susceptibility for cystic fibrosis transmembrane conductance regulator misfolding mutants. | Mol Biol Cell | 2022 | https://conductscience.org/library/papers/35389766 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CANX | 821 | PubTator's text mining | https://conductscience.org/library/genes/821 | NCBI Gene |
| CFTR | 1080 | PubTator's text mining | https://conductscience.org/library/genes/1080 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40964320
GET https://conductscience.org/api/papers/v1/40964320/references?page=2